Researchers Develop Simple Prostate Cancer Assays for ERG

Researchers Develop Simple Prostate Cancer Assays for ERG
shutterstock_166437050In terms of early prostate cancer detection methods, more is better. Researchers at Pacific Northwest National Laboratory in Richland, Washington determined that the ETS-related gene (ERG) is a reliable biomarker for prostate cancer and can be detected using simple assays available in the clinic. Standard procedure for detecting prostate cancer includes a serum analysis for prostate-specific antigen (PSA), a urine analysis for prostate cancer antigen 3 (PCA3), and a tissue analysis for alpha-methylacyl-coA racemase (AMACR), all of which are proteins that are over produced in cases of prostate cancer. However, other proteins are associated with prostate cancer, including the oncoprotein ERG. The researchers at Pacific Northwest National Laboratory noted that there are no commercially available serological-based assays for ERG and investigated how they could develop one in the study "Analytical Platform Evaluation for Quantification of ERG in Prostate Cancer Using Protein and mRNA Detection Methods," published in Journal of Translational Medicine. After considering a variety of technologies capable of analyzing proteins, the research team chose to deve
Subscribe or to access all post and page content.

Tagged , .

Maureen Newman is a science columnist for Pulmonary Hypertension News. She is currently a PhD student studying biomedical engineering at University of Rochester, working towards a career of research in biomaterials for drug delivery and regenerative medicine. She is an integral part of Dr. Danielle Benoit's laboratory, where she is investigating bone-homing therapeutics for osteoporosis treatment.

Leave a Comment

Your email address will not be published. Required fields are marked *